Skip to main navigation
  Menu

ASLAN Pharmaceuticals

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
EN
english中文

Investor Relations

Investor Relations

  • Investor Home
  • Corporate Information
  • Stock Information
  • News & Events
  • Financial Information
    • SEC Filings
    • Quarterly Results
    • Analyst Coverage
  • Shareholder Services

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Alerts sign up

Required fields denoted by an asterisk ().
Alert type

SEC Filings

SEC Filings

SEC Filing Keyword Search

Filing date Form Description Filing Group View
Jul 14, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001193125-21-214522.pdf
0001193125-21-214522.rtf
0001193125-21-214522.xls
May 11, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001564590-21-026305.pdf
0001564590-21-026305.rtf
0001564590-21-026305.xls
Apr 23, 2021 20-F

Registration of securities of foreign private issuers pursuant to section 12(b) or (g)

Annual Filings
View HTML
0001564590-21-020241.pdf
0001564590-21-020241.rtf
0001564590-21-020241.xls
EX-101.INS - XBRL INSTANCE DOCUMENT
Apr 22, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001193125-21-126446.pdf
0001193125-21-126446.rtf
0001193125-21-126446.xls
Mar 31, 2021 EFFECT

EFFECT

Other
View HTML
9999999995-21-001242.pdf
9999999995-21-001242.rtf
9999999995-21-001242.xls
Mar 31, 2021 UPLOAD

UPLOAD

Other
View HTML
0000000000-21-003845.pdf
0000000000-21-003845.rtf
Mar 31, 2021 CORRESP

CORRESP

Other
View HTML
0001193125-21-101166.pdf
0001193125-21-101166.rtf
0001193125-21-101166.xls
Mar 26, 2021 F-3

Registration statement for certain foreign private issuers offered for certain transactions

Registration Statements
View HTML
0001193125-21-096567.pdf
0001193125-21-096567.rtf
0001193125-21-096567.xls
Mar 18, 2021 6-K

Report of foreign issuer rules 13a-16 and 15d-16 of the Securities Exchange Act

Current Reports
View HTML
0001564590-21-014010.pdf
0001564590-21-014010.rtf
0001564590-21-014010.xls
Mar 04, 2021 424B5

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Registration Statements
View HTML
0001193125-21-068370.pdf
0001193125-21-068370.rtf
0001193125-21-068370.xls

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Current page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • …
  • Next page Next ›
  • Last page Last »

Shareholder Tools

  • Print Page

    Print Page

  • RSS Feeds

    RSS Feeds

  • E-mail Alerts

    E-mail Alerts

Company

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
  • Terms and Conditions

Footer Social Icons

Careers

For more information on employment opportunities at ASLAN, please contact us at careers@aslanpharma.com

Contact Us

Singapore Headquarters
3 Temasek Avenue, Level 18,
Singapore 039190
Tel: +65 6817 9598

contact@aslanpharma.com